{"ticker": {"uuid": "f11304ef-c5ae-4053-88ac-d08c5bd31e2b", "symbol": "TVGN", "name": "Tevogen Bio Holdings Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Dr. Saadi boosts control at Tevogen Bio Holdings (TVGN) with stock grant", "summary": "Dr. Ryan H. Saadi, CEO of Tevogen Bio Holdings (TVGN), has increased his beneficial ownership to 59.7% of the company's common stock, totaling 3,709,567 shares. This surge in control stems from a restricted stock grant of 1,220,000 shares received on July 10, 2026, as compensatio", "url": "https://www.stocktitan.net/sec-filings/TVGN/schedule-13d-a-tevogen-bio-holdings-inc-amended-major-shareholder-rep-6776cf744ce9.html", "source_name": "Stock Titan", "published_at": "2026-07-15T02:13:33", "published_display": "15 Jul 2026 02:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A Tevogen Bio Holdings Inc. For: 14 July By Investing.com", "summary": "This article reports that Tevogen Bio Holdings Inc. has filed a Form 13D/A on July 14, 2026. This SEC filing indicates a change in beneficial ownership of the company's shares.", "url": "https://ng.investing.com/news/stock-market-news/form-13da-tevogen-bio-holdings-inc-for-14-july-93CH-2599781", "source_name": "Investing.com Nigeria", "published_at": "2026-07-15T02:00:00", "published_display": "15 Jul 2026 02:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio Announces 2026 Annual Meeting of Stockholders", "summary": "Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has announced its 2026 Annual Meeting of Stockholders will be held virtually on Monday, August 24, 2026. Stockholders of record as of July 23, 2026, will be eligible to vote. The company also provided deadlines for stockholder proposals an", "url": "https://www.biospace.com/press-releases/tevogen-bio-announces-2026-annual-meeting-of-stockholders", "source_name": "BioSpace", "published_at": "2026-07-14T23:44:46", "published_display": "14 Jul 2026 23:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Tevogen Bio Holdings Inc. \u2013 NASDAQ:TVGNW", "summary": "The article focuses on the \"Price to book forward\" for Tevogen Bio Holdings Inc., traded on NASDAQ under the symbol TVGNW. It appears to be an entry from a financial data platform like TradingView, providing specific financial metrics for the company. The content primarily lists ", "url": "https://www.tradingview.com/symbols/NASDAQ-TVGNW/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T20:40:05", "published_display": "14 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen stockholders face a July 23 deadline to submit proposals", "summary": "Tevogen Bio (Nasdaq: TVGN) has announced its 2026 Annual Meeting of Stockholders for Monday, August 24, 2026, to be held virtually. Stockholders of record as of July 23, 2026, are eligible to vote. Due to the meeting date being more than one year after the previous meeting, stock", "url": "https://www.stocktitan.net/news/TVGN/tevogen-bio-announces-2026-annual-meeting-of-j42jgq6u6l2i.html", "source_name": "Stock Titan", "published_at": "2026-07-14T02:12:25", "published_display": "14 Jul 2026 02:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tevogen Bio Holdings(TVGN) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "Moomoo", "published_at": "2026-07-12T20:14:20+00:00", "published_display": "12 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio (TVGN) awards director 40,000 restricted shares tied to revenue goals", "summary": "Tevogen Bio Holdings Inc. Director Goh Keow Lin was granted 40,000 restricted common shares under the 2024 Omnibus Incentive Plan. These shares vest in three equal installments upon reaching specified anniversaries of the grant date or aggregate revenue milestones of $50 million,", "url": "https://www.stocktitan.net/sec-filings/TVGN/form-4-tevogen-bio-holdings-inc-insider-trading-activity-24baba299b6e.html", "source_name": "Stock Titan", "published_at": "2026-07-10T23:10:12", "published_display": "10 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio (TVGN) awards CFO 40,000 restricted shares with revenue vesting targets", "summary": "Tevogen Bio Holdings Inc. (TVGN) has granted its CFO, Kirti Desai, 40,000 restricted shares of common stock at no cost. These shares will vest in three equal tranches, contingent on both service anniversaries and the company achieving aggregate revenue targets of $50 million, $10", "url": "https://www.stocktitan.net/sec-filings/TVGN/form-4-tevogen-bio-holdings-inc-insider-trading-activity-ef95c4fa2fd2.html", "source_name": "Stock Titan", "published_at": "2026-07-10T22:40:03", "published_display": "10 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio (TVGN) awards 40,000 restricted shares to director Feike", "summary": "Tevogen Bio (TVGN) director Jeffrey L. Feike was granted 40,000 restricted common shares under the company's 2024 Omnibus Incentive Plan. These shares, valued at $0.00 per share, will vest in three equal installments tied to both service anniversaries and Tevogen Bio achieving ag", "url": "https://www.stocktitan.net/sec-filings/TVGN/form-4-tevogen-bio-holdings-inc-insider-trading-activity-08fc35559d39.html", "source_name": "Stock Titan", "published_at": "2026-07-10T22:40:03", "published_display": "10 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio (TVGN) awards 40,000 restricted stock shares to director Victor J. Sordillo", "summary": "Tevogen Bio (TVGN) has granted 40,000 shares of restricted common stock to director Victor J. Sordillo under its 2024 Omnibus Incentive Plan. These shares were awarded at no cost and will vest in three equal installments, subject to service-based anniversaries and the company ach", "url": "https://www.stocktitan.net/sec-filings/TVGN/form-4-tevogen-bio-holdings-inc-insider-trading-activity-71e3a2a07b13.html", "source_name": "Stock Titan", "published_at": "2026-07-10T22:11:58", "published_display": "10 Jul 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Tevogen Bio Holdings Inc For: 10 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Tevogen Bio Holdings Inc. dated July 10. The filing indicates insider trading activity for the company. The stock symbol TVGN is mentioned with a performance of -10.28%.", "url": "https://ng.investing.com/news/stock-market-news/form-4-tevogen-bio-holdings-inc-for-10-july-93CH-2595663", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T22:11:57", "published_display": "10 Jul 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Tevogen Bio Holdings Inc. Insider Trading Activity", "summary": "Tevogen Bio Holdings Inc. Director Curtis L. Patton reported an acquisition of 40,000 shares of restricted common stock through a Form 4 filing. The shares were granted under the company\u2019s 2024 Omnibus Incentive Plan, with vesting tied to service requirements and revenue mileston", "url": "https://www.stocktitan.net/sec-filings/TVGN/form-4-tevogen-bio-holdings-inc-insider-trading-activity-96979defab36.html", "source_name": "Stock Titan", "published_at": "2026-07-10T21:09:57", "published_display": "10 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio (TVGN) awards 40,000 performance-based restricted shares to director", "summary": "Tevogen Bio Holdings Inc. (TVGN) has granted director Susan M. Podlogar 40,000 performance-based restricted shares under its 2024 Omnibus Incentive Plan. These shares vest in three equal installments, contingent on both continued service and the company achieving aggregate revenu", "url": "https://www.stocktitan.net/sec-filings/TVGN/form-4-tevogen-bio-holdings-inc-insider-trading-activity-705b0d460814.html", "source_name": "Stock Titan", "published_at": "2026-07-10T21:09:57", "published_display": "10 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio (TVGN) grants CEO Ryan Saadi 1.22M restricted stock units", "summary": "Tevogen Bio Holdings Inc. (TVGN) has granted its CEO, Ryan H. Saadi, 1,220,000 shares of restricted common stock under the company's 2024 Omnibus Incentive Plan. These shares will vest in four equal annual installments starting July 10, 2033, contingent on his continued service. ", "url": "https://www.stocktitan.net/sec-filings/TVGN/form-4-tevogen-bio-holdings-inc-insider-trading-activity-6415da1e388c.html", "source_name": "Stock Titan", "published_at": "2026-07-10T21:09:57", "published_display": "10 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Tevogen Bio Holdings Inc. \u2013 FWB:G280", "summary": "The article focuses on the Enterprise Value to EBITDA forward for Tevogen Bio Holdings Inc. (FWB:G280), traded on the Frankfurt Stock Exchange. It appears to be a financial data point or analysis provided by a platform like TradingView, indicating a key valuation metric for the b", "url": "https://www.tradingview.com/symbols/FWB-G280/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T20:09:32", "published_display": "27 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Tevogen Bio Holdings Inc. \u2013 NASDAQ:TVGN", "summary": "This article displays the forward Enterprise Value to EBIT for Tevogen Bio Holdings Inc. (NASDAQ: TVGN) on the TradingView platform. It presents financial data for the company, accessible through the \"Financials\" section of its profile.", "url": "https://www.tradingview.com/symbols/NASDAQ-TVGN/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T21:40:04", "published_display": "26 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Tevogen Bio Holdings Inc. \u2013 NASDAQ:TVGN", "summary": "This article provides an \"Enterprise value to revenue forward\" metric for Tevogen Bio Holdings Inc., traded on NASDAQ under the symbol TVGN. The content is primarily a data point placeholder from TradingView, indicating the value and change of this financial metric. It does not o", "url": "https://www.tradingview.com/symbols/NASDAQ-TVGN/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T20:39:32", "published_display": "26 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Tevogen Bio Holdings Inc. \u2013 FWB:G280", "summary": "This article provides financial data for Tevogen Bio Holdings Inc. (FWB:G280), specifically focusing on its enterprise value to revenue forward. The content appears to be a financial data snippet from TradingView, offering a snapshot of the company's valuation metric on the Frank", "url": "https://www.tradingview.com/symbols/FWB-G280/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T19:40:04", "published_display": "26 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio (NASDAQ: TVGN) registers 375,000 shares for resale by Patel Family", "summary": "Tevogen Bio (NASDAQ: TVGN) has registered up to 375,000 shares of common stock for resale by a selling stockholder, the Patel Family, through a prospectus filed with the SEC. These shares are issuable upon the exercise of Pre-Funded Warrants issued in May 2026. Tevogen Bio will n", "url": "https://www.stocktitan.net/sec-filings/TVGN/424b3-tevogen-bio-holdings-inc-prospectus-filed-pursuant-to-rule-424--fd5789870a15.html", "source_name": "Stock Titan", "published_at": "2026-06-26T13:10:36", "published_display": "26 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Tevogen Bio Holdings Inc. \u2013 NASDAQ:TVGN", "summary": "The article presents the \"Price to book forward\" financial metric for Tevogen Bio Holdings Inc. (NASDAQ: TVGN). It appears to be an entry on a financial data platform like TradingView, displaying key financial information for the biotechnology company. The content also includes e", "url": "https://www.tradingview.com/symbols/NASDAQ-TVGN/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T10:10:36", "published_display": "26 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Tevogen Bio Holdings Inc. SEC Filing", "summary": "Tevogen Bio Holdings Inc. (NASDAQ: TVGN) has filed an EFFECT form with the SEC, indicating that a previous filing (Form S-3 shelf registration) has become effective. The filing shows an effectiveness date of June 25, 2026, at 4:30 P.M. UTC, making the company's previously filed s", "url": "https://www.stocktitan.net/sec-filings/TVGN/effect-tevogen-bio-holdings-inc-sec-filing-e8bba711a5f2.html", "source_name": "Stock Titan", "published_at": "2026-06-26T10:10:36", "published_display": "26 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Tevogen Bio Holdings Inc. \u2013 FWB:G280", "summary": "The article provides a financial overview of Tevogen Bio Holdings Inc. (FWB:G280) on the Frankfurt Stock Exchange, specifically focusing on its price-to-sales forward metric. It indicates that the market was closed at the time of publication with no trades, and the information is", "url": "https://www.tradingview.com/symbols/FWB-G280/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T02:10:36", "published_display": "26 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Tevogen Bio Holdings Inc. \u2013 FWB:G280", "summary": "This article provides financial data for Tevogen Bio Holdings Inc. (FWB:G280) on TradingView. It specifically highlights the company's price to earnings forward metric. The market for this stock is currently closed with no trades.", "url": "https://www.tradingview.com/symbols/FWB-G280/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T01:09:41", "published_display": "26 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio Holdings Inc (TVGN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Tevogen Bio Holdings Inc (TVGN), outlining future EPS and revenue growth estimates. It notes that relevant financial data for the company's earnings, revenue, net profit, and EBIT forecasts have not yet been disclosed by the company.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tvgn/earnings", "source_name": "TradingKey", "published_at": "2026-06-22T15:41:29", "published_display": "22 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio Holdings Inc (TVGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Tevogen Bio Holdings Inc (TVGN), featuring its current stock price, market cap, and a detailed breakdown of various technical indicators and moving averages. While support and resistance data are not yet disclosed, the indicators show", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tvgn/technical", "source_name": "TradingKey", "published_at": "2026-06-18T14:40:08", "published_display": "18 Jun 2026 14:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio Holdings Inc (TVGNW) Institutional Confidence", "summary": "The article details the institutional confidence in Tevogen Bio Holdings Inc (TVGNW), providing a list of institutional shareholders and their shareholdings. The stock is currently trading at $0.041, down 16.36%, with institutional confidence being one of the key metrics assessed", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tvgnw/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:20", "published_display": "18 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio Holdings Inc (TVGNW) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Tevogen Bio Holdings Inc (TVGNW), detailing key financial metrics such as P/E, P/B, P/S, and P/CF ratios. It indicates that relevant data for these metrics have not yet been disclosed by the company. The report also includes current ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tvgnw/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:20", "published_display": "18 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio Holdings Inc (TVGN) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Tevogen Bio Holdings Inc (TVGN), showing its current stock price and market capitalization. It notes that relevant data for key valuation metrics like P/E, P/B, P/S, and P/CF ratios have not yet been disclosed by the company. The over", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tvgn/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T06:10:06", "published_display": "18 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio Holdings Inc (TVGN) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides an analysis of Tevogen Bio Holdings Inc (TVGN) financial health using TradingKey's stock score system. The analysis highlights that relevant financial data for profitability, operational efficiency, growth potential, and shareholder returns have not been dis", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tvgn/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T06:09:20", "published_display": "18 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Announces Formation of a Healthcare Services Initiative", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tevogen-announces-formation-healthcare-services-193000366.html", "source_name": "GlobeNewswire", "published_at": "2026-06-09T19:30:00+00:00", "published_display": "09 Jun 2026 19:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen weighs $100M in potential MSO, CRO revenue with new unit", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQZE1WNEt3UktNUUlNY2Q1dTl3MkpEV3VtSXJVemJmbDIwX2UyNWZlWFg5WFFWQ0FUZjdmUHZxZjRHOVhDSHoxU3h6RzlIa2VSV0hYMXVPeHpiLTZRTkRtOEgyMHFZYVlJUnA4bmFudVltVGxnSDloNlNzZFExY0tFXzVQdTJoQ1pObGtJakI5cmJxYUtSQ0JPdFRjSkk4aC1TR2MxengwQ3NOZXc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tevogen-advances-strategic-acquisition-initiatives-163000156.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T16:30:00+00:00", "published_display": "28 May 2026 16:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen outlines biotech, AI and healthcare services vision", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNY0M5RmplUkJBSG9mN1JldDk2c0J0aUo5VklZNkxRTTlBUzFydkJDazF0azQwZHRHS1pHeWhvNnFwQy1ycE5kZjhCMnBQMF9aSHZaSHJiMUpSVUtmbElpemFMODFENW40aUcweTB1RDA3TkIySHRUQnZUVXpWVU9DSjhOOVpWT2dSZG1FQmV0bldJcUZoczh6WVJPWkJwdWVIMXJMMjd6SkNKdTJMV0h4TENEU09TdjZ6a1VrMHJwcFk?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tevogen-signs-letter-intent-evaluate-161500099.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T16:15:00+00:00", "published_display": "21 May 2026 16:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Existing backer pays 14% premium in Tevogen\u2019s new $3M cash raise", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNUk56VWZxc19BNFZhVkJ5VVI5RXRLX2JUbmRpRUtGcHl2VjJoMmhDVFJuZWtuOGZtNklKaWwzTlgzTnI3ZEZiVHJSay1vODVRQWFmd1NoR0pKSHhsMFVKZGNESUFqT2VRVnZyMXZtUzM3cGNlZXgwZW1EbjAxYS1lUjJMSlNrNkFCeTN6RERrYm9Gdm9SMWpEMlY2MVJ2cHd6ZGFrckI5Um9IaEVPYXp1d2N1Z3QtOFNWdFlVM2VR?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPRGJ5ZnRuMmsydVJLejd5dG41VnAtQVdhdzc4T0NELXZUdi1Bb0FIREw0cVJ1RGxmLXhEYnNwSG1SQkU4RlNFLUxBNS12UWttQ2IxakR6Y1hzeklka2RaRVNicnIzdVhiTG1MLVo0VEJBRTFZV2JrRUNmRDhMZlM4TkZKRm16MUJyZmZCVm16ZExGd1h2TTVHMVRLNlFZanVrbVc3QTkxZw?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tevogen (TVGN) Soars 11% as Firm Gears Up for AI Training Commercialization", "summary": "", "url": "https://finance.yahoo.com/sectors/technology/articles/tevogen-tvgn-soars-11-firm-012439359.html", "source_name": "Insider Monkey", "published_at": "2026-05-05T01:24:39+00:00", "published_display": "05 May 2026 01:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio (NASDAQ: TVGN) adds governance, pay and related-party details", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPVUlTWENfdkhHSzN1YVlIU3V2YmtpTGlmc0M5TmloZEdhV1JzQ1Q4VWF4MkZJbko4U2xZZFZiSlJCLTBTdzBMcXV6M25TQTdVaC1IZHMySG00T3VCNnRYV1pCODdsSkFzTURnb1RNZDk3VWpYTlRFTy1wd3p2VVlZLTJHbl9Pa2JsaWJIbGpGQmp5TVdoamZKSEFDQU1QNTN4ZDhRbzZRZG91WkpINFJFc05hb0Y?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen.AI Nears Completion of PredicTcell\u2122 Training; Initiates Commercial Readiness and Debuts Internal Application Portal", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tevogen-ai-nears-completion-predictcell-155000752.html", "source_name": "GlobeNewswire", "published_at": "2026-04-27T15:50:00+00:00", "published_display": "27 Apr 2026 15:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tevogen Bio (NASDAQ: TVGN) warned on Nasdaq $50M, $15M value tests", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPUnRNdDZDeDQ0aGQyMkVUMUpoeUc0U2JpaUl5ZVE5S1BwT0JDOTFGdXhfOEhNNHRlRkdReFZ0NDIzWU14Nl9USGlPZkpYbWNMR0JENmxyQ0RTSlY3c0VlUnJHbnFDSmkzYm44VFhiSldsMUJRR2RWZk5STURMZjNYYlU3UmVWTXNqSEg2NkY2RENQSklpSXlYbFUtZVNuZ1ViNVRaVHhDWXc4WDh6UXZCTUJIWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tevogen Bio (TVGN) Stock Pre-Market (-4.1%): New Diversified Strategy Met With Skepticism", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxNWkZ0UmtLMVliaGk0RW5QcWk3YUZ2WXJtRFZEeVEtQjJXOHR5ZmdMSVVBSktWXzlPVWpGak9JWG5uV3RvUUZPT1oyNnRra2dWd2hsU1JYYzkxVC13MHg2VFFZT2ZaekFGYmlabHQ4Ty0tZE53bUUtU2gxZFJ2UXZvYUNVTW5KQ1BDclJxdE9xYTU4VVNCUm5LOG82NklnOHdhTXNlR0FUWHJNRjQ3Z2libjl2NC1Cb2JITS1SQlZ5ODF6MmNNTDltaWRuSlFxSUJNNkh4Y2Q5UkdRaDhWQ3pYS2RJbHcyMGM?oc=5", "source_name": "Trefis", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inside Tevogen's $50M expansion push and the team picked to run it", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQc2tNM1o5czhYRkxTeTBjSGNpZTZZV0drR0tma1hDNGlES29UWk5kZjE1aEhlWW9QbnFXQTlMTTNxYkZNX0hPSjVTMzFlcFFWM2YtbFctTFdnWGowQ1YyV0FPTWJCdi11d1d1bDJlaHZLb1RZYTdJZVMyMXlHV0pRaTg1UEVLZjFOaWMzN2t6SVdJVC1WRjI3MTFsMXMtVXF2dGlFMUtGOC1zSkozMHZycWZCcU0?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPdzBqRHZET2lqSUI2T3hKeEZUZjQ4U0Y2RVVCT2JqdDUwNlJfV004UEZtdmN0dTZhTFl0Z0U3QjdBeExzUXdiWWY5UmFOcEZ4X1BkeC1OYlFPd2tQbzUyOUp3NVE0blZISzFaa2ZjbE5mU0V0dmdiZV9TVFlYdWUwaFkwQmdIZFNGUWU0MnotWQ?oc=5", "source_name": "Market source", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Announces Reverse Stock Split", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxOZjdiUTlJNnZTcm55dHFGcEI3RHJJd1RJeWZwdVY2N2JOb0tPeEZvQkNGRnZ1MmgxSFJ1dkJxMHluUTMxLTJZNmlEYVNqS0p2Y1BMTzhfZTJESXVwTGxaZ3FwOFp6TUQ4czdhQ1JVNUZ5M1U5V3hZUkY1cnZQbGZLeHZBM2dPZS1Ha04w?oc=5", "source_name": "Market source", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Expect Breakeven For Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Before Long", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNZjA4ZXZVa3RRVlI5bWM5SkdVaWdCMndpX3JiUk1tb1lqQ2I0WXJ0MC1WaVFfLS1XSmc1VF9CMHhhZWkzUURpWldObHV0cktnMEV3bGNyYTFFZWVIdkk5MnlMOXRlUC1Eei1fN1pTZUxDTnVFV0Y5cWlTVm9TNHhkWmg5V0sza2pMN3NJ?oc=5", "source_name": "Market source", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio (TVGN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE96R0R5SGtuX3ppNURWckF2RDE1VUlIaFJvUEtma0JfbjdwSWc1VkxfdWJBTnh4N0VEWFphb3dkb2otV0x1SVZndDdpdmpNaHVVMElOc0VZYlF5dw?oc=5", "source_name": "MarketBeat", "published_at": "2024-02-18T13:08:29+00:00", "published_display": "18 Feb 2024 13:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Dr. Saadi boosts control at Tevogen Bio Holdings (TVGN) with stock grant", "summary": "Dr. Ryan H. Saadi, CEO of Tevogen Bio Holdings (TVGN), has increased his beneficial ownership to 59.7% of the company's common stock, totaling 3,709,567 shares. This surge in control stems from a restricted stock grant of 1,220,000 shares received on July 10, 2026, as compensatio", "url": "https://www.stocktitan.net/sec-filings/TVGN/schedule-13d-a-tevogen-bio-holdings-inc-amended-major-shareholder-rep-6776cf744ce9.html", "source_name": "Stock Titan", "published_at": "2026-07-15T02:13:33", "published_display": "15 Jul 2026 02:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A Tevogen Bio Holdings Inc. For: 14 July By Investing.com", "summary": "This article reports that Tevogen Bio Holdings Inc. has filed a Form 13D/A on July 14, 2026. This SEC filing indicates a change in beneficial ownership of the company's shares.", "url": "https://ng.investing.com/news/stock-market-news/form-13da-tevogen-bio-holdings-inc-for-14-july-93CH-2599781", "source_name": "Investing.com Nigeria", "published_at": "2026-07-15T02:00:00", "published_display": "15 Jul 2026 02:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio Announces 2026 Annual Meeting of Stockholders", "summary": "Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has announced its 2026 Annual Meeting of Stockholders will be held virtually on Monday, August 24, 2026. Stockholders of record as of July 23, 2026, will be eligible to vote. The company also provided deadlines for stockholder proposals an", "url": "https://www.biospace.com/press-releases/tevogen-bio-announces-2026-annual-meeting-of-stockholders", "source_name": "BioSpace", "published_at": "2026-07-14T23:44:46", "published_display": "14 Jul 2026 23:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Tevogen Bio Holdings Inc. \u2013 NASDAQ:TVGNW", "summary": "The article focuses on the \"Price to book forward\" for Tevogen Bio Holdings Inc., traded on NASDAQ under the symbol TVGNW. It appears to be an entry from a financial data platform like TradingView, providing specific financial metrics for the company. The content primarily lists ", "url": "https://www.tradingview.com/symbols/NASDAQ-TVGNW/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T20:40:05", "published_display": "14 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen stockholders face a July 23 deadline to submit proposals", "summary": "Tevogen Bio (Nasdaq: TVGN) has announced its 2026 Annual Meeting of Stockholders for Monday, August 24, 2026, to be held virtually. Stockholders of record as of July 23, 2026, are eligible to vote. Due to the meeting date being more than one year after the previous meeting, stock", "url": "https://www.stocktitan.net/news/TVGN/tevogen-bio-announces-2026-annual-meeting-of-j42jgq6u6l2i.html", "source_name": "Stock Titan", "published_at": "2026-07-14T02:12:25", "published_display": "14 Jul 2026 02:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio Holdings(TVGN) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "Moomoo", "published_at": "2026-07-12T20:14:20+00:00", "published_display": "12 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio (TVGN) awards director 40,000 restricted shares tied to revenue goals", "summary": "Tevogen Bio Holdings Inc. Director Goh Keow Lin was granted 40,000 restricted common shares under the 2024 Omnibus Incentive Plan. These shares vest in three equal installments upon reaching specified anniversaries of the grant date or aggregate revenue milestones of $50 million,", "url": "https://www.stocktitan.net/sec-filings/TVGN/form-4-tevogen-bio-holdings-inc-insider-trading-activity-24baba299b6e.html", "source_name": "Stock Titan", "published_at": "2026-07-10T23:10:12", "published_display": "10 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio (TVGN) awards CFO 40,000 restricted shares with revenue vesting targets", "summary": "Tevogen Bio Holdings Inc. (TVGN) has granted its CFO, Kirti Desai, 40,000 restricted shares of common stock at no cost. These shares will vest in three equal tranches, contingent on both service anniversaries and the company achieving aggregate revenue targets of $50 million, $10", "url": "https://www.stocktitan.net/sec-filings/TVGN/form-4-tevogen-bio-holdings-inc-insider-trading-activity-ef95c4fa2fd2.html", "source_name": "Stock Titan", "published_at": "2026-07-10T22:40:03", "published_display": "10 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio (TVGN) awards 40,000 restricted shares to director Feike", "summary": "Tevogen Bio (TVGN) director Jeffrey L. Feike was granted 40,000 restricted common shares under the company's 2024 Omnibus Incentive Plan. These shares, valued at $0.00 per share, will vest in three equal installments tied to both service anniversaries and Tevogen Bio achieving ag", "url": "https://www.stocktitan.net/sec-filings/TVGN/form-4-tevogen-bio-holdings-inc-insider-trading-activity-08fc35559d39.html", "source_name": "Stock Titan", "published_at": "2026-07-10T22:40:03", "published_display": "10 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio (TVGN) awards 40,000 restricted stock shares to director Victor J. Sordillo", "summary": "Tevogen Bio (TVGN) has granted 40,000 shares of restricted common stock to director Victor J. Sordillo under its 2024 Omnibus Incentive Plan. These shares were awarded at no cost and will vest in three equal installments, subject to service-based anniversaries and the company ach", "url": "https://www.stocktitan.net/sec-filings/TVGN/form-4-tevogen-bio-holdings-inc-insider-trading-activity-71e3a2a07b13.html", "source_name": "Stock Titan", "published_at": "2026-07-10T22:11:58", "published_display": "10 Jul 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Tevogen Bio Holdings Inc For: 10 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Tevogen Bio Holdings Inc. dated July 10. The filing indicates insider trading activity for the company. The stock symbol TVGN is mentioned with a performance of -10.28%.", "url": "https://ng.investing.com/news/stock-market-news/form-4-tevogen-bio-holdings-inc-for-10-july-93CH-2595663", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T22:11:57", "published_display": "10 Jul 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Tevogen Bio Holdings Inc. Insider Trading Activity", "summary": "Tevogen Bio Holdings Inc. Director Curtis L. Patton reported an acquisition of 40,000 shares of restricted common stock through a Form 4 filing. The shares were granted under the company\u2019s 2024 Omnibus Incentive Plan, with vesting tied to service requirements and revenue mileston", "url": "https://www.stocktitan.net/sec-filings/TVGN/form-4-tevogen-bio-holdings-inc-insider-trading-activity-96979defab36.html", "source_name": "Stock Titan", "published_at": "2026-07-10T21:09:57", "published_display": "10 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio (TVGN) awards 40,000 performance-based restricted shares to director", "summary": "Tevogen Bio Holdings Inc. (TVGN) has granted director Susan M. Podlogar 40,000 performance-based restricted shares under its 2024 Omnibus Incentive Plan. These shares vest in three equal installments, contingent on both continued service and the company achieving aggregate revenu", "url": "https://www.stocktitan.net/sec-filings/TVGN/form-4-tevogen-bio-holdings-inc-insider-trading-activity-705b0d460814.html", "source_name": "Stock Titan", "published_at": "2026-07-10T21:09:57", "published_display": "10 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio (TVGN) grants CEO Ryan Saadi 1.22M restricted stock units", "summary": "Tevogen Bio Holdings Inc. (TVGN) has granted its CEO, Ryan H. Saadi, 1,220,000 shares of restricted common stock under the company's 2024 Omnibus Incentive Plan. These shares will vest in four equal annual installments starting July 10, 2033, contingent on his continued service. ", "url": "https://www.stocktitan.net/sec-filings/TVGN/form-4-tevogen-bio-holdings-inc-insider-trading-activity-6415da1e388c.html", "source_name": "Stock Titan", "published_at": "2026-07-10T21:09:57", "published_display": "10 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Tevogen Bio Holdings Inc. \u2013 FWB:G280", "summary": "The article focuses on the Enterprise Value to EBITDA forward for Tevogen Bio Holdings Inc. (FWB:G280), traded on the Frankfurt Stock Exchange. It appears to be a financial data point or analysis provided by a platform like TradingView, indicating a key valuation metric for the b", "url": "https://www.tradingview.com/symbols/FWB-G280/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T20:09:32", "published_display": "27 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Tevogen Bio Holdings Inc. \u2013 NASDAQ:TVGN", "summary": "This article displays the forward Enterprise Value to EBIT for Tevogen Bio Holdings Inc. (NASDAQ: TVGN) on the TradingView platform. It presents financial data for the company, accessible through the \"Financials\" section of its profile.", "url": "https://www.tradingview.com/symbols/NASDAQ-TVGN/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T21:40:04", "published_display": "26 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Tevogen Bio Holdings Inc. \u2013 NASDAQ:TVGN", "summary": "This article provides an \"Enterprise value to revenue forward\" metric for Tevogen Bio Holdings Inc., traded on NASDAQ under the symbol TVGN. The content is primarily a data point placeholder from TradingView, indicating the value and change of this financial metric. It does not o", "url": "https://www.tradingview.com/symbols/NASDAQ-TVGN/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T20:39:32", "published_display": "26 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Tevogen Bio Holdings Inc. \u2013 FWB:G280", "summary": "This article provides financial data for Tevogen Bio Holdings Inc. (FWB:G280), specifically focusing on its enterprise value to revenue forward. The content appears to be a financial data snippet from TradingView, offering a snapshot of the company's valuation metric on the Frank", "url": "https://www.tradingview.com/symbols/FWB-G280/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T19:40:04", "published_display": "26 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio (NASDAQ: TVGN) registers 375,000 shares for resale by Patel Family", "summary": "Tevogen Bio (NASDAQ: TVGN) has registered up to 375,000 shares of common stock for resale by a selling stockholder, the Patel Family, through a prospectus filed with the SEC. These shares are issuable upon the exercise of Pre-Funded Warrants issued in May 2026. Tevogen Bio will n", "url": "https://www.stocktitan.net/sec-filings/TVGN/424b3-tevogen-bio-holdings-inc-prospectus-filed-pursuant-to-rule-424--fd5789870a15.html", "source_name": "Stock Titan", "published_at": "2026-06-26T13:10:36", "published_display": "26 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Tevogen Bio Holdings Inc. \u2013 NASDAQ:TVGN", "summary": "The article presents the \"Price to book forward\" financial metric for Tevogen Bio Holdings Inc. (NASDAQ: TVGN). It appears to be an entry on a financial data platform like TradingView, displaying key financial information for the biotechnology company. The content also includes e", "url": "https://www.tradingview.com/symbols/NASDAQ-TVGN/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T10:10:36", "published_display": "26 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Tevogen Bio Holdings Inc. SEC Filing", "summary": "Tevogen Bio Holdings Inc. (NASDAQ: TVGN) has filed an EFFECT form with the SEC, indicating that a previous filing (Form S-3 shelf registration) has become effective. The filing shows an effectiveness date of June 25, 2026, at 4:30 P.M. UTC, making the company's previously filed s", "url": "https://www.stocktitan.net/sec-filings/TVGN/effect-tevogen-bio-holdings-inc-sec-filing-e8bba711a5f2.html", "source_name": "Stock Titan", "published_at": "2026-06-26T10:10:36", "published_display": "26 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Tevogen Bio Holdings Inc. \u2013 FWB:G280", "summary": "The article provides a financial overview of Tevogen Bio Holdings Inc. (FWB:G280) on the Frankfurt Stock Exchange, specifically focusing on its price-to-sales forward metric. It indicates that the market was closed at the time of publication with no trades, and the information is", "url": "https://www.tradingview.com/symbols/FWB-G280/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T02:10:36", "published_display": "26 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Tevogen Bio Holdings Inc. \u2013 FWB:G280", "summary": "This article provides financial data for Tevogen Bio Holdings Inc. (FWB:G280) on TradingView. It specifically highlights the company's price to earnings forward metric. The market for this stock is currently closed with no trades.", "url": "https://www.tradingview.com/symbols/FWB-G280/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T01:09:41", "published_display": "26 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio Holdings Inc (TVGN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Tevogen Bio Holdings Inc (TVGN), outlining future EPS and revenue growth estimates. It notes that relevant financial data for the company's earnings, revenue, net profit, and EBIT forecasts have not yet been disclosed by the company.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tvgn/earnings", "source_name": "TradingKey", "published_at": "2026-06-22T15:41:29", "published_display": "22 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio Holdings Inc (TVGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Tevogen Bio Holdings Inc (TVGN), featuring its current stock price, market cap, and a detailed breakdown of various technical indicators and moving averages. While support and resistance data are not yet disclosed, the indicators show", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tvgn/technical", "source_name": "TradingKey", "published_at": "2026-06-18T14:40:08", "published_display": "18 Jun 2026 14:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio Holdings Inc (TVGNW) Institutional Confidence", "summary": "The article details the institutional confidence in Tevogen Bio Holdings Inc (TVGNW), providing a list of institutional shareholders and their shareholdings. The stock is currently trading at $0.041, down 16.36%, with institutional confidence being one of the key metrics assessed", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tvgnw/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:20", "published_display": "18 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio Holdings Inc (TVGNW) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Tevogen Bio Holdings Inc (TVGNW), detailing key financial metrics such as P/E, P/B, P/S, and P/CF ratios. It indicates that relevant data for these metrics have not yet been disclosed by the company. The report also includes current ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tvgnw/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:20", "published_display": "18 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio Holdings Inc (TVGN) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Tevogen Bio Holdings Inc (TVGN), showing its current stock price and market capitalization. It notes that relevant data for key valuation metrics like P/E, P/B, P/S, and P/CF ratios have not yet been disclosed by the company. The over", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tvgn/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T06:10:06", "published_display": "18 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio Holdings Inc (TVGN) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides an analysis of Tevogen Bio Holdings Inc (TVGN) financial health using TradingKey's stock score system. The analysis highlights that relevant financial data for profitability, operational efficiency, growth potential, and shareholder returns have not been dis", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tvgn/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T06:09:20", "published_display": "18 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Announces Formation of a Healthcare Services Initiative", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tevogen-announces-formation-healthcare-services-193000366.html", "source_name": "GlobeNewswire", "published_at": "2026-06-09T19:30:00+00:00", "published_display": "09 Jun 2026 19:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen weighs $100M in potential MSO, CRO revenue with new unit", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQZE1WNEt3UktNUUlNY2Q1dTl3MkpEV3VtSXJVemJmbDIwX2UyNWZlWFg5WFFWQ0FUZjdmUHZxZjRHOVhDSHoxU3h6RzlIa2VSV0hYMXVPeHpiLTZRTkRtOEgyMHFZYVlJUnA4bmFudVltVGxnSDloNlNzZFExY0tFXzVQdTJoQ1pObGtJakI5cmJxYUtSQ0JPdFRjSkk4aC1TR2MxengwQ3NOZXc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tevogen-advances-strategic-acquisition-initiatives-163000156.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T16:30:00+00:00", "published_display": "28 May 2026 16:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen outlines biotech, AI and healthcare services vision", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNY0M5RmplUkJBSG9mN1JldDk2c0J0aUo5VklZNkxRTTlBUzFydkJDazF0azQwZHRHS1pHeWhvNnFwQy1ycE5kZjhCMnBQMF9aSHZaSHJiMUpSVUtmbElpemFMODFENW40aUcweTB1RDA3TkIySHRUQnZUVXpWVU9DSjhOOVpWT2dSZG1FQmV0bldJcUZoczh6WVJPWkJwdWVIMXJMMjd6SkNKdTJMV0h4TENEU09TdjZ6a1VrMHJwcFk?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tevogen-signs-letter-intent-evaluate-161500099.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T16:15:00+00:00", "published_display": "21 May 2026 16:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Existing backer pays 14% premium in Tevogen\u2019s new $3M cash raise", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNUk56VWZxc19BNFZhVkJ5VVI5RXRLX2JUbmRpRUtGcHl2VjJoMmhDVFJuZWtuOGZtNklKaWwzTlgzTnI3ZEZiVHJSay1vODVRQWFmd1NoR0pKSHhsMFVKZGNESUFqT2VRVnZyMXZtUzM3cGNlZXgwZW1EbjAxYS1lUjJMSlNrNkFCeTN6RERrYm9Gdm9SMWpEMlY2MVJ2cHd6ZGFrckI5Um9IaEVPYXp1d2N1Z3QtOFNWdFlVM2VR?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPRGJ5ZnRuMmsydVJLejd5dG41VnAtQVdhdzc4T0NELXZUdi1Bb0FIREw0cVJ1RGxmLXhEYnNwSG1SQkU4RlNFLUxBNS12UWttQ2IxakR6Y1hzeklka2RaRVNicnIzdVhiTG1MLVo0VEJBRTFZV2JrRUNmRDhMZlM4TkZKRm16MUJyZmZCVm16ZExGd1h2TTVHMVRLNlFZanVrbVc3QTkxZw?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen (TVGN) Soars 11% as Firm Gears Up for AI Training Commercialization", "summary": "", "url": "https://finance.yahoo.com/sectors/technology/articles/tevogen-tvgn-soars-11-firm-012439359.html", "source_name": "Insider Monkey", "published_at": "2026-05-05T01:24:39+00:00", "published_display": "05 May 2026 01:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio (NASDAQ: TVGN) adds governance, pay and related-party details", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPVUlTWENfdkhHSzN1YVlIU3V2YmtpTGlmc0M5TmloZEdhV1JzQ1Q4VWF4MkZJbko4U2xZZFZiSlJCLTBTdzBMcXV6M25TQTdVaC1IZHMySG00T3VCNnRYV1pCODdsSkFzTURnb1RNZDk3VWpYTlRFTy1wd3p2VVlZLTJHbl9Pa2JsaWJIbGpGQmp5TVdoamZKSEFDQU1QNTN4ZDhRbzZRZG91WkpINFJFc05hb0Y?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen.AI Nears Completion of PredicTcell\u2122 Training; Initiates Commercial Readiness and Debuts Internal Application Portal", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/tevogen-ai-nears-completion-predictcell-155000752.html", "source_name": "GlobeNewswire", "published_at": "2026-04-27T15:50:00+00:00", "published_display": "27 Apr 2026 15:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio (NASDAQ: TVGN) warned on Nasdaq $50M, $15M value tests", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPUnRNdDZDeDQ0aGQyMkVUMUpoeUc0U2JpaUl5ZVE5S1BwT0JDOTFGdXhfOEhNNHRlRkdReFZ0NDIzWU14Nl9USGlPZkpYbWNMR0JENmxyQ0RTSlY3c0VlUnJHbnFDSmkzYm44VFhiSldsMUJRR2RWZk5STURMZjNYYlU3UmVWTXNqSEg2NkY2RENQSklpSXlYbFUtZVNuZ1ViNVRaVHhDWXc4WDh6UXZCTUJIWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio (TVGN) Stock Pre-Market (-4.1%): New Diversified Strategy Met With Skepticism", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxNWkZ0UmtLMVliaGk0RW5QcWk3YUZ2WXJtRFZEeVEtQjJXOHR5ZmdMSVVBSktWXzlPVWpGak9JWG5uV3RvUUZPT1oyNnRra2dWd2hsU1JYYzkxVC13MHg2VFFZT2ZaekFGYmlabHQ4Ty0tZE53bUUtU2gxZFJ2UXZvYUNVTW5KQ1BDclJxdE9xYTU4VVNCUm5LOG82NklnOHdhTXNlR0FUWHJNRjQ3Z2libjl2NC1Cb2JITS1SQlZ5ODF6MmNNTDltaWRuSlFxSUJNNkh4Y2Q5UkdRaDhWQ3pYS2RJbHcyMGM?oc=5", "source_name": "Trefis", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inside Tevogen's $50M expansion push and the team picked to run it", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQc2tNM1o5czhYRkxTeTBjSGNpZTZZV0drR0tma1hDNGlES29UWk5kZjE1aEhlWW9QbnFXQTlMTTNxYkZNX0hPSjVTMzFlcFFWM2YtbFctTFdnWGowQ1YyV0FPTWJCdi11d1d1bDJlaHZLb1RZYTdJZVMyMXlHV0pRaTg1UEVLZjFOaWMzN2t6SVdJVC1WRjI3MTFsMXMtVXF2dGlFMUtGOC1zSkozMHZycWZCcU0?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPdzBqRHZET2lqSUI2T3hKeEZUZjQ4U0Y2RVVCT2JqdDUwNlJfV004UEZtdmN0dTZhTFl0Z0U3QjdBeExzUXdiWWY5UmFOcEZ4X1BkeC1OYlFPd2tQbzUyOUp3NVE0blZISzFaa2ZjbE5mU0V0dmdiZV9TVFlYdWUwaFkwQmdIZFNGUWU0MnotWQ?oc=5", "source_name": "Market source", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Announces Reverse Stock Split", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxOZjdiUTlJNnZTcm55dHFGcEI3RHJJd1RJeWZwdVY2N2JOb0tPeEZvQkNGRnZ1MmgxSFJ1dkJxMHluUTMxLTJZNmlEYVNqS0p2Y1BMTzhfZTJESXVwTGxaZ3FwOFp6TUQ4czdhQ1JVNUZ5M1U5V3hZUkY1cnZQbGZLeHZBM2dPZS1Ha04w?oc=5", "source_name": "Market source", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Expect Breakeven For Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Before Long", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNZjA4ZXZVa3RRVlI5bWM5SkdVaWdCMndpX3JiUk1tb1lqQ2I0WXJ0MC1WaVFfLS1XSmc1VF9CMHhhZWkzUURpWldObHV0cktnMEV3bGNyYTFFZWVIdkk5MnlMOXRlUC1Eei1fN1pTZUxDTnVFV0Y5cWlTVm9TNHhkWmg5V0sza2pMN3NJ?oc=5", "source_name": "Market source", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tevogen Bio (TVGN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE96R0R5SGtuX3ppNURWckF2RDE1VUlIaFJvUEtma0JfbjdwSWc1VkxfdWJBTnh4N0VEWFphb3dkb2otV0x1SVZndDdpdmpNaHVVMElOc0VZYlF5dw?oc=5", "source_name": "MarketBeat", "published_at": "2024-02-18T13:08:29+00:00", "published_display": "18 Feb 2024 13:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 87, "total_relevant": 55, "sentiment_summary": {"positive": 3, "negative": 2, "neutral": 50, "score": 50, "total": 55, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 18.7, "count": 34}, {"event": "earnings", "label": "Earnings", "weight": 7.56, "count": 16}, {"event": "deals", "label": "Deals and strategy", "weight": 2.2, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 3, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 5.06, "latest_week": "2026-07-10", "one_week_move": -12.3, "four_week_move": -51.7, "twelve_week_move": -31.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.900129, "market_dynamics_buy_signal": false, "relative_strength": -80.757881, "fair_value_gap": -91.1, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 40.203, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-12.3% over one week, -51.7% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 59, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 17}, {"label": "Market source", "count": 10}, {"label": "TradingView", "count": 9}, {"label": "TradingKey", "count": 6}, {"label": "GlobeNewswire", "count": 4}, {"label": "Investing.com Nigeria", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "BioSpace", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 46}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 34}, {"label": "Earnings", "count": 16}, {"label": "Deals and strategy", "count": 4}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "46", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-12.3% over one week, -51.7% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Dr. Saadi boosts control at Tevogen Bio Holdings (TVGN) with stock grant"}], "updated_at": "2026-07-17T13:08:49.739574+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}